Illumina Viral Surveillance Panel v2

Next‑generation sequencing (NGS) assay with hybrid capture enrichment for the detection and whole‑genome sequencing of approximately 200 RNA and DNA viruses relevant to public health. It integrates library preparation, enrichment, sequencing, and data analysis into an optimized workflow of about two days.

Detailed Description

Principle of operation

The panel can start from RNA, DNA, or total nucleic acid extracted from host or environmental samples. When the sample contains RNA, it is denatured and converted into double‑stranded cDNA; subsequently, the material is fragmented by tagmentation with Bead‑Linked Transposomes for Enrichment (EBLTL). Libraries are indexed with unique dual indexes, pooled, and subjected to hybrid‑capture enrichment with probes that cover the target viral genomes to generate whole‑genome sequencing data.

Clinical applications

It is aimed at outbreak genomic surveillance, zoonotic surveillance, mutation tracking, and variant monitoring. The workflow supports clinical and remnant clinical samples such as plasma, serum, skin lesions, and nasopharyngeal swabs, as well as environmental samples, including wastewater, for regional surveillance and early detection of viral sequences.

Benefits

Compared to metagenomic shotgun sequencing, hybrid capture enrichment reduces unnecessary sequencing of host material and non‑target microorganisms, decreases the need for high read depths, reduces costs, and favors higher throughput. Additionally, the document indicates that, compared to targeted methods such as amplicon sequencing, hybrid capture offers more uniform coverage of the viral genome and greater capacity to identify mutations and divergent sequences. The workflow is compatible with automation, requires little hands‑on time, and can be completed in approximately two days.

Key results or indicators

In multiviric samples prepared with 1000 genomic copies per reaction, the panel recovered on average 99.1% of the Human adenovirus E genome and 99.4% of the Influenza A virus (H3N2) genome, while shotgun sequencing recovered on average 1.9% and 0%, respectively. In remnant clinical samples, all samples enriched with Viral Surveillance Panel v2 showed higher viral detection sensitivity than shotgun metagenomics. In wastewater, it also demonstrated higher detection sensitivity in complex samples with low viral load, even when shotgun sequencing increased the total number of reads approximately six‑fold.

Technology used

It uses NGS with hybrid capture target enrichment, tagmentation with EBLTL, unique dual indexing of up to 384 libraries, and analysis with DRAGEN Microbial Enrichment Plus App on BaseSpace Sequence Hub. Bioinformatic processing includes sample quality control, reference‑guided alignment against a curated viral database, variant calling, consensus sequence generation, antiviral resistance prediction for influenza A/B, and integration with Pangolin and Nextclade for phylogenetic assignment in compatible viruses.

Intended user / audience

This assay is intended for public health organizations and researchers who need viral surveillance, viral genome characterization, and analysis of complex samples in research contexts.

Considerations or limitations

It is a product for research use only and not for diagnostic procedures. The protocol is optimized for 10–100 ng of purified total RNA, DNA, or total nucleic acid; smaller amounts or lower quality material may reduce library yield. It is not recommended to normalize samples by equal mass; it is recommended to use the same volume of extracted nucleic acid per sample. It is recommended to pool samples with similar viral titers; mixing very different titers may bias results. In complex samples, such as wastewater, off‑target reads may be expected if other microbial nucleic acids are present.

Other relevant technical information

The workflow supports sequencing on Illumina MiniSeq, MiSeq, NextSeq 550, NextSeq 1000, and NextSeq 2000 systems. For good quality samples, the general recommendation is a minimum of 2 million reads per sample with a read length of 2 × 150 bp; for wastewater, the document recommends a minimum of 8 million reads per sample.

Key Features

Covers approximately 200 RNA and DNA viruses, including viruses of high public health relevance.
Hybrid capture enrichment for viral detection and whole‑genome sequencing with lower depth requirement than shotgun metagenomics.
Compatible with host and environmental samples, including plasma, serum, skin lesions, nasopharyngeal swabs, and wastewater.
Integrated workflow from library preparation to bioinformatic analysis in approximately 2 days with little hands‑on time.
Unique dual indexing and multiplexing capacity of up to 384 libraries.
Analysis with DRAGEN Microbial Enrichment Plus App and support for quality control, variants, consensi, and phylogenetic assignment.

Presentation Details

Format

Targeted sequencing protocol for VSPv2 available as a kit in four 96‑sample sets. Each kit includes reagents for 32 reactions and, using the recommended 3‑plex format, can process 96 samples. Additionally, the panel can be purchased alone.

Kit Contents
The content is distributed across several boxes including reagents such as Illumina Viral Surveillance Panel v2, Illumina RNA Prep with Enrichment (L) Tagmentation library preparation reagents, Illumina Purification Beads, and an Illumina DNA/RNA UD Indexes adapter plate.
References
Illumina Viral Surveillance Panel v2 Kit, Set A (96 samples) 20108081
Illumina Viral Surveillance Panel v2 Kit, Set B (96 samples) 20108082
Illumina Viral Surveillance Panel v2 Kit, Set C (96 samples) 20108083
Illumina Viral Surveillance Panel v2 Kit, Set D (96 samples) 20108084
Illumina Viral Surveillance Panel v2, Panel Only (96 samples) 20123403
×

Area:

Microbiology, Virus

Brand:

Consult our experts

Google reCaptcha: Invalid site key.

Related products

NimoTest® Fetal RHD qPCR kit

NIMoTest® Fetal RHD qPCR kit is a kit for determining the fetal RHD genotype from maternal plasma. It is intended for the monitoring of RhD-negative pregnant women to guide anti-RhD immunoprophylaxis and adapt the monitoring of immunised women. Detailed description The kit is designed for duplex quantitative PCR (pPCR) amplification of exons 5 and 7…
BeDia Genomics
Real Time PCR (qPCR)

Genvinset® MTHFR multiplex

In vitro diagnostic kit based on real-time PCR for the simultaneous detection of the A1298C and C677T polymorphisms in the MTHFR gene. Detailed description Operating principle The assay is based on real-time PCR (Real-Time PCR) amplification using TaqMan® hydrolysis probes. Two primer pairs are used to amplify specific regions of the MTHFR gene containing the…
Blackhills Diagnostic Resources
Real Time PCR (qPCR)

Genvinset® FIIFV multiplex

In vitro diagnostic kit for the simultaneous detection of the G20210A mutation in the prothrombin gene (FII) and the G1691A mutation in Factor V using real-time PCR. Detailed description Operating principle The assay is based on the real-time PCR (Real-Time PCR) amplification of specific regions of the FII and FV factor genes containing the mutations…
Blackhills Diagnostic Resources
Real Time PCR (qPCR)

Genvinset® PAI-1/FXIII multiplex

In vitro diagnostic kit based on real-time PCR for the simultaneous detection of the -675 PAI-1 4G/5G polymorphism in the SERPINE1 gene and rs5985 (Val34Leu) in the F13A1 gene, associated with the risk of thrombosis. Detailed description Operating principle Genvinset® PAI-1/FXIII multiplex uses real-time PCR technology (Real-Time PCR) with TaqMan® hydrolysis probes for the qualitative…
Blackhills Diagnostic Resources
Real Time PCR (qPCR)